tetano
Editor, Senior Moderator
Infect Genet Evol
. 2021 Dec 16;105191.
doi: 10.1016/j.meegid.2021.105191. Online ahead of print.
Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt
Mohamed G Seadawy[SUP] 1 [/SUP], Ahmed F Gad[SUP] 2 [/SUP], Sabah A Abo-Elmaaty[SUP] 3 [/SUP], Mervat G Hassan[SUP] 3 [/SUP]
Affiliations
Abstract
Recently, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in Coronavirus Disease 2019 (COVID-19) outbreak. A new SARS-CoV-2 strain is expected to emerge in late 2020, including B.1.1.7. The high transmission rate of SARS-CoV-2 B.1.1.7 has raised public health concerns in several countries. Hence, in this study, we assessed the sequencing of SARS-COV2 to reveals the prevalence of the SARS-CoV-2 Alpha variant (B 1.1.7) in Egypt. We found that the viral transmission of the alpha variant is expanding. Moreover, based on hospitalizations and case fatality rates, there is a potential for increasing severity. There was no effect on susceptibility to Emergency Use Authorization monoclonal antibody treatments. However, there was minimal impact on neutralization by convalescent and post-vaccination sera. Samples have been clustered into the 20D sub clade for the majority of them. The eight samples shown in our study are considered the first recorded samples with the Alpha variant in Egypt. Therefore, The Egyptian government, represented by the Ministry of Health, must take all measures to examine the compatibility of the currently used vaccines with this new strain and the feasibility of the treatment protocol presently used with such strains developed in the Arab Republic of Egypt.
Keywords: Alpha variant; B 1.1.7; COVID-19; Egypt; SARS-CoV-2.
. 2021 Dec 16;105191.
doi: 10.1016/j.meegid.2021.105191. Online ahead of print.
Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt
Mohamed G Seadawy[SUP] 1 [/SUP], Ahmed F Gad[SUP] 2 [/SUP], Sabah A Abo-Elmaaty[SUP] 3 [/SUP], Mervat G Hassan[SUP] 3 [/SUP]
Affiliations
- PMID: 34923158
- DOI: 10.1016/j.meegid.2021.105191
Abstract
Recently, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in Coronavirus Disease 2019 (COVID-19) outbreak. A new SARS-CoV-2 strain is expected to emerge in late 2020, including B.1.1.7. The high transmission rate of SARS-CoV-2 B.1.1.7 has raised public health concerns in several countries. Hence, in this study, we assessed the sequencing of SARS-COV2 to reveals the prevalence of the SARS-CoV-2 Alpha variant (B 1.1.7) in Egypt. We found that the viral transmission of the alpha variant is expanding. Moreover, based on hospitalizations and case fatality rates, there is a potential for increasing severity. There was no effect on susceptibility to Emergency Use Authorization monoclonal antibody treatments. However, there was minimal impact on neutralization by convalescent and post-vaccination sera. Samples have been clustered into the 20D sub clade for the majority of them. The eight samples shown in our study are considered the first recorded samples with the Alpha variant in Egypt. Therefore, The Egyptian government, represented by the Ministry of Health, must take all measures to examine the compatibility of the currently used vaccines with this new strain and the feasibility of the treatment protocol presently used with such strains developed in the Arab Republic of Egypt.
Keywords: Alpha variant; B 1.1.7; COVID-19; Egypt; SARS-CoV-2.